Q1 EPS Estimates for Arcus Biosciences Lifted by Wedbush

Arcus Biosciences, Inc. (NYSE:RCUS) – Analysts at Wedbush increased their Q1 2025 earnings per share (EPS) estimates for shares of Arcus Biosciences in a research report issued on Tuesday, February 18th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($1.31) for the quarter, up from their prior estimate of ($1.41). Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.23) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.07) EPS, FY2026 earnings at ($4.77) EPS, FY2027 earnings at ($4.02) EPS and FY2028 earnings at ($0.91) EPS.

RCUS has been the subject of a number of other research reports. Morgan Stanley lowered their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. HC Wainwright reduced their target price on Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Finally, Bank of America reduced their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Arcus Biosciences Stock Up 3.0 %

Shares of NYSE:RCUS opened at $11.06 on Friday. The stock has a fifty day simple moving average of $13.92 and a two-hundred day simple moving average of $15.55. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -3.51 and a beta of 0.84. Arcus Biosciences has a 12-month low of $10.63 and a 12-month high of $20.31. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Gilead Sciences Inc. bought a new position in Arcus Biosciences in the fourth quarter worth approximately $447,610,000. FMR LLC grew its stake in Arcus Biosciences by 6.9% in the third quarter. FMR LLC now owns 4,467,557 shares of the company’s stock worth $68,309,000 after purchasing an additional 286,766 shares in the last quarter. Woodline Partners LP grew its stake in Arcus Biosciences by 1.3% in the fourth quarter. Woodline Partners LP now owns 3,523,937 shares of the company’s stock worth $52,471,000 after purchasing an additional 45,497 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Arcus Biosciences by 32.9% in the third quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock worth $37,263,000 after purchasing an additional 603,222 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Arcus Biosciences by 11.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company’s stock worth $25,348,000 after purchasing an additional 178,351 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.